AU2017378783A1 - Cyclic dinucleotide sting agonists for cancer treatment - Google Patents
Cyclic dinucleotide sting agonists for cancer treatment Download PDFInfo
- Publication number
- AU2017378783A1 AU2017378783A1 AU2017378783A AU2017378783A AU2017378783A1 AU 2017378783 A1 AU2017378783 A1 AU 2017378783A1 AU 2017378783 A AU2017378783 A AU 2017378783A AU 2017378783 A AU2017378783 A AU 2017378783A AU 2017378783 A1 AU2017378783 A1 AU 2017378783A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- alkynyl
- alkenyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C[n]1c(N=CNC2=*)c2nc1 Chemical compound C[n]1c(N=CNC2=*)c2nc1 0.000 description 6
- DMQJHEHHWMWGBH-KGVWEPGKSA-N Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O DMQJHEHHWMWGBH-KGVWEPGKSA-N 0.000 description 3
- GKWLKXKXJYLBGO-UHFFFAOYSA-N CC(C)[n]1c(cnnc2N)c2nc1 Chemical compound CC(C)[n]1c(cnnc2N)c2nc1 GKWLKXKXJYLBGO-UHFFFAOYSA-N 0.000 description 2
- QOMIZXMHBKHHPI-UHFFFAOYSA-N CC(C)[n]1c(nnnc2N)c2nc1 Chemical compound CC(C)[n]1c(nnnc2N)c2nc1 QOMIZXMHBKHHPI-UHFFFAOYSA-N 0.000 description 2
- PJIKJWZUUZCBMP-UHFFFAOYSA-N CC(C)[n]1nnc2c1nccc2Cl Chemical compound CC(C)[n]1nnc2c1nccc2Cl PJIKJWZUUZCBMP-UHFFFAOYSA-N 0.000 description 2
- SDSVBSGTPJSAAS-UHFFFAOYSA-N CC(C)[n]1nnc2c1nccc2N Chemical compound CC(C)[n]1nnc2c1nccc2N SDSVBSGTPJSAAS-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- BHUCLZKQTSRSAY-UHFFFAOYSA-N C=C1NC(N)=Nc2c1nc[n]2C(C(C1)OP(OCC(C(C2)O3)OC2[n]2c4ncnc(N)c4cc2)(S)=O)OC1CO[P]3=O Chemical compound C=C1NC(N)=Nc2c1nc[n]2C(C(C1)OP(OCC(C(C2)O3)OC2[n]2c4ncnc(N)c4cc2)(S)=O)OC1CO[P]3=O BHUCLZKQTSRSAY-UHFFFAOYSA-N 0.000 description 1
- WRXUDHYWQLDMFG-UHFFFAOYSA-N C=P(O)OC(C(COP(O)(OC(CCC(COC1CO)[n]2c(NC(NC3=O)=O)c3nc2)C1O)=O)OCC(CC1)[n]2c(ncnc3N)c3nc2)C1O Chemical compound C=P(O)OC(C(COP(O)(OC(CCC(COC1CO)[n]2c(NC(NC3=O)=O)c3nc2)C1O)=O)OCC(CC1)[n]2c(ncnc3N)c3nc2)C1O WRXUDHYWQLDMFG-UHFFFAOYSA-N 0.000 description 1
- ZCVPLCZDFTXKSB-UHFFFAOYSA-N C=P(OCC(C(C1OP(O)(OCC2OC3[n]4c(ncnc5N)c5nc4)=O)O)OC1[n]1c(N=C(N)NC4=S)c4nc1)OC2C3O Chemical compound C=P(OCC(C(C1OP(O)(OCC2OC3[n]4c(ncnc5N)c5nc4)=O)O)OC1[n]1c(N=C(N)NC4=S)c4nc1)OC2C3O ZCVPLCZDFTXKSB-UHFFFAOYSA-N 0.000 description 1
- HNZKXAAYIJCELB-UHFFFAOYSA-N CC(C)[n]1c(C=CNC2)c2nc1 Chemical compound CC(C)[n]1c(C=CNC2)c2nc1 HNZKXAAYIJCELB-UHFFFAOYSA-N 0.000 description 1
- GSTFEDXYLJOASP-UHFFFAOYSA-N CC(C)[n]1c(C=NNC2=O)c2nc1 Chemical compound CC(C)[n]1c(C=NNC2=O)c2nc1 GSTFEDXYLJOASP-UHFFFAOYSA-N 0.000 description 1
- FHNZYLCFLUYYAJ-UHFFFAOYSA-N CC(C)[n]1c(F)nc2c1ncnc2N Chemical compound CC(C)[n]1c(F)nc2c1ncnc2N FHNZYLCFLUYYAJ-UHFFFAOYSA-N 0.000 description 1
- MMVXHMIFFAGTTP-UHFFFAOYSA-N CC(C)[n]1c(N=C(N)NC2=O)c2nc1 Chemical compound CC(C)[n]1c(N=C(N)NC2=O)c2nc1 MMVXHMIFFAGTTP-UHFFFAOYSA-N 0.000 description 1
- YDXYXPFTXQYYLA-UHFFFAOYSA-N CC(C)[n]1c(N=NNC2)c2nc1 Chemical compound CC(C)[n]1c(N=NNC2)c2nc1 YDXYXPFTXQYYLA-UHFFFAOYSA-N 0.000 description 1
- LLWXDRCTMRAEHR-UHFFFAOYSA-N CC(C)[n]1c(NC(N)=CC2=O)c2nc1 Chemical compound CC(C)[n]1c(NC(N)=CC2=O)c2nc1 LLWXDRCTMRAEHR-UHFFFAOYSA-N 0.000 description 1
- RZIIMNOJHLWYNA-UHFFFAOYSA-N CC(C)[n]1c(ncnc2Cl)c2nc1 Chemical compound CC(C)[n]1c(ncnc2Cl)c2nc1 RZIIMNOJHLWYNA-UHFFFAOYSA-N 0.000 description 1
- URGLBEHKAGLPSW-UHFFFAOYSA-N CC(C)[n]1c2nc(Cl)nc(N)c2nc1 Chemical compound CC(C)[n]1c2nc(Cl)nc(N)c2nc1 URGLBEHKAGLPSW-UHFFFAOYSA-N 0.000 description 1
- WIJJVFRRTKRLDN-UHFFFAOYSA-N CC(C)[n]1c2nc(F)nc(N)c2nc1 Chemical compound CC(C)[n]1c2nc(F)nc(N)c2nc1 WIJJVFRRTKRLDN-UHFFFAOYSA-N 0.000 description 1
- SNRRUVSDZBYKMB-UHFFFAOYSA-N CC(C)[n]1nnc2c1ncnc2N Chemical compound CC(C)[n]1nnc2c1ncnc2N SNRRUVSDZBYKMB-UHFFFAOYSA-N 0.000 description 1
- DJEGXCSZPXPBJI-UHFFFAOYSA-N CC(C)c(cn[n]12)c1N=C(N)NC2=O Chemical compound CC(C)c(cn[n]12)c1N=C(N)NC2=O DJEGXCSZPXPBJI-UHFFFAOYSA-N 0.000 description 1
- GNAZEKNFVIEROL-UHFFFAOYSA-N CC(C)c1c2ncnc(N)[n]2nc1 Chemical compound CC(C)c1c2ncnc(N)[n]2nc1 GNAZEKNFVIEROL-UHFFFAOYSA-N 0.000 description 1
- HLHOXUPUXBCGJL-UHFFFAOYSA-N CC(C)c1ccc2[n]1ncnc2N Chemical compound CC(C)c1ccc2[n]1ncnc2N HLHOXUPUXBCGJL-UHFFFAOYSA-N 0.000 description 1
- QWCWYKDHDMAMMC-UHFFFAOYSA-N CC(C)c1cnc2[n]1N=CNC2 Chemical compound CC(C)c1cnc2[n]1N=CNC2 QWCWYKDHDMAMMC-UHFFFAOYSA-N 0.000 description 1
- DBJQPZWYNHAIBE-BYXXVGLGSA-N CC(CNC=N)[C@@]([C@@H]([C@@H](COP(O)(O[C@H]1[C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@H](CO2)[C@H]1O)=O)O)OP2(C)=O)(N)O Chemical compound CC(CNC=N)[C@@]([C@@H]([C@@H](COP(O)(O[C@H]1[C@H]([n]2c(N=C(N)NC3=O)c3nc2)O[C@H](CO2)[C@H]1O)=O)O)OP2(C)=O)(N)O DBJQPZWYNHAIBE-BYXXVGLGSA-N 0.000 description 1
- SFPFRHORTKYSAB-UHFFFAOYSA-N CCOc1nc(N)nc2c1nc[n]2C(C)C Chemical compound CCOc1nc(N)nc2c1nc[n]2C(C)C SFPFRHORTKYSAB-UHFFFAOYSA-N 0.000 description 1
- WNBMDLUFRFGTKF-UHFFFAOYSA-N CP(OC(C(COP(O)(OC1C([n]2c(N=C(N)NC3=O)c3nc2)OC(CO)C1O)=O)OC1[n](cc2F)c3c2c(N)ncn3)C1O)=O Chemical compound CP(OC(C(COP(O)(OC1C([n]2c(N=C(N)NC3=O)c3nc2)OC(CO)C1O)=O)OC1[n](cc2F)c3c2c(N)ncn3)C1O)=O WNBMDLUFRFGTKF-UHFFFAOYSA-N 0.000 description 1
- PGOVVVRQKVHSOH-JIMCYBNRSA-N CP(OCC([C@H]1O)SC[C@]1([n]1nnc2c1N=C(N)NC2=O)OP(OC1)(S)=O)(O[C@@H](C2)[C@@H]1O[C@H]2c1cnc2[n]1ncnc2N)=O Chemical compound CP(OCC([C@H]1O)SC[C@]1([n]1nnc2c1N=C(N)NC2=O)OP(OC1)(S)=O)(O[C@@H](C2)[C@@H]1O[C@H]2c1cnc2[n]1ncnc2N)=O PGOVVVRQKVHSOH-JIMCYBNRSA-N 0.000 description 1
- JHBKZFZUKKUUPM-SNEOCVOESA-N CP(OC[C@H]([C@@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)F)O[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@H]3O)=O Chemical compound CP(OC[C@H]([C@@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)F)O[C@H]1[n]1c(N=C(N)NC4=O)c4nc1)(O[C@H]2[C@H]3O)=O JHBKZFZUKKUUPM-SNEOCVOESA-N 0.000 description 1
- XPGVHFGYPFQMGD-JYXCDCNCSA-N CP(OC[C@H]([C@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)O)O[C@H]1[n]1c(C=CNC4=O)c4nc1)(O[C@H]2[C@H]3O)=O Chemical compound CP(OC[C@H]([C@H]([C@H]1OP(O)(OC[C@H]2O[C@H]3[n]4c(ncnc5N)c5nc4)=O)O)O[C@H]1[n]1c(C=CNC4=O)c4nc1)(O[C@H]2[C@H]3O)=O XPGVHFGYPFQMGD-JYXCDCNCSA-N 0.000 description 1
- JONBYGVPWBZMRT-YZLACOAKSA-N C[C@@H]([C@H]1C)[C@@H](COP(O)(O[C@H]2[C@H]([n]3c(C=CNC4=O)c4nc3)O[C@H](COC)[C@H]2O)=O)O[C@H]1[n]1c(ncnc2N)c2nc1 Chemical compound C[C@@H]([C@H]1C)[C@@H](COP(O)(O[C@H]2[C@H]([n]3c(C=CNC4=O)c4nc3)O[C@H](COC)[C@H]2O)=O)O[C@H]1[n]1c(ncnc2N)c2nc1 JONBYGVPWBZMRT-YZLACOAKSA-N 0.000 description 1
- ZVOCBPQFDKWAIP-UHFFFAOYSA-N C[n](cc1F)c2c1c(N)ncn2 Chemical compound C[n](cc1F)c2c1c(N)ncn2 ZVOCBPQFDKWAIP-UHFFFAOYSA-N 0.000 description 1
- PESGUQRDJASXOR-UHFFFAOYSA-N C[n]1c(N=CNC2=O)c2nc1 Chemical compound C[n]1c(N=CNC2=O)c2nc1 PESGUQRDJASXOR-UHFFFAOYSA-N 0.000 description 1
- MXOUBPWTHPIGIM-UHFFFAOYSA-N Cc1c(N)[n](CNC=C)nc1 Chemical compound Cc1c(N)[n](CNC=C)nc1 MXOUBPWTHPIGIM-UHFFFAOYSA-N 0.000 description 1
- FJRNORWUSSOHGG-UHFFFAOYSA-N Cc1cnc2[n]1ncnc2N Chemical compound Cc1cnc2[n]1ncnc2N FJRNORWUSSOHGG-UHFFFAOYSA-N 0.000 description 1
- BEFDHGMTNXHUFP-OFOUMVFDSA-N NC1=NC=NC23N([C@@H](C4)OC(COP(O)(O[C@H]5[C@H]([n]6c(N=C(N)NC7=O)c7nc6)OC(CO6)[C@H]5F)S)[C@H]4OP6(O)=S)C=CC2C13 Chemical compound NC1=NC=NC23N([C@@H](C4)OC(COP(O)(O[C@H]5[C@H]([n]6c(N=C(N)NC7=O)c7nc6)OC(CO6)[C@H]5F)S)[C@H]4OP6(O)=S)C=CC2C13 BEFDHGMTNXHUFP-OFOUMVFDSA-N 0.000 description 1
- GDZGPZQNJBCWOZ-RNPZHLOYSA-N Nc1c2nc[n]([C@@H]([C@@H]3OC4)O[C@]4(COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)S[C@H](CO5)[C@@H]4F)(S)=O)[C@H]3OP5(S)=O)c2ncn1 Chemical compound Nc1c2nc[n]([C@@H]([C@@H]3OC4)O[C@]4(COP(O[C@H]4[C@H]([n]5c(N=C(N)NC6=O)c6nc5)S[C@H](CO5)[C@@H]4F)(S)=O)[C@H]3OP5(S)=O)c2ncn1 GDZGPZQNJBCWOZ-RNPZHLOYSA-N 0.000 description 1
- IFSJZFXDECKHBF-YTWGRVFTSA-N Nc1ccnc2c1nc[n]2[C@@](CO[C@@H]1COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)([C@@H]1OP3(S)=O)F Chemical compound Nc1ccnc2c1nc[n]2[C@@](CO[C@@H]1COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)([C@@H]1OP3(S)=O)F IFSJZFXDECKHBF-YTWGRVFTSA-N 0.000 description 1
- PMVFWGTZQOCLPV-BTTVZHTHSA-N Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O[C@@](CS[C@@H]2CO3)([C@@H]2O)N2NNC4=C2N=C(N)NC4=O)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncn[n]2c1ncc2[C@@H](C1)O[C@H](COP(O[C@@](CS[C@@H]2CO3)([C@@H]2O)N2NNC4=C2N=C(N)NC4=O)(S)=O)[C@H]1OP3(S)=O PMVFWGTZQOCLPV-BTTVZHTHSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Nc1ncnc2c1nc[nH]2 Chemical compound Nc1ncnc2c1nc[nH]2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- VRCHMBRVIQUHAY-UHFFFAOYSA-N Nc1ncnc2c1nc[n]2C(C1F)OC(COP(O)(OC2C([n]3c(N=C(N)NC4=O)c4nc3)OC(CO3)C2F)=O)C1OP3=O Chemical compound Nc1ncnc2c1nc[n]2C(C1F)OC(COP(O)(OC2C([n]3c(N=C(N)NC4=O)c4nc3)OC(CO3)C2F)=O)C1OP3=O VRCHMBRVIQUHAY-UHFFFAOYSA-N 0.000 description 1
- SQJBIIRNUUAXMI-UHFFFAOYSA-N Nc1ncnc2c1nc[n]2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2O)(S)=O)C1OP3=O Chemical compound Nc1ncnc2c1nc[n]2C(C1F)OC(COP(OC2C([n]3c(N=C(N)NC4=O)c4nc3)SC(CO3)C2O)(S)=O)C1OP3=O SQJBIIRNUUAXMI-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-OPSRSLIDSA-N Nc1ncnc2c1nc[n]2[C@@H](C1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H](C1F)O[C@H](COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1OP3(S)=O YSUIQYOGTINQIN-OPSRSLIDSA-N 0.000 description 1
- GDZGPZQNJBCWOZ-UNKCTKLQSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1OC2)OC2(COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1OC2)OC2(COP(O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O GDZGPZQNJBCWOZ-UNKCTKLQSA-N 0.000 description 1
- YSUIQYOGTINQIN-CLMXYZJCSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](CO[P@](O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1O[P@@]3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@H]1F)O[C@H](CO[P@](O[C@H]2[C@H]([n]3c(N=C(N)NC4=O)c4nc3)O[C@H](CO3)[C@H]2F)(S)=O)[C@H]1O[P@@]3(S)=O YSUIQYOGTINQIN-CLMXYZJCSA-N 0.000 description 1
- DMQJHEHHWMWGBH-GVGNCSFUSA-N Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2C([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nn[n]2[C@@H](C1(F)F)O[C@H](COP(O[C@H]2C([n]3c(N=C(N)NC4=O)c4nc3)S[C@H](CO3)[C@@H]2F)(S)=O)[C@H]1OP3(S)=O DMQJHEHHWMWGBH-GVGNCSFUSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436712P | 2016-12-20 | 2016-12-20 | |
| US62/436,712 | 2016-12-20 | ||
| PCT/US2017/066557 WO2018118665A1 (en) | 2016-12-20 | 2017-12-15 | Cyclic dinucleotide sting agonists for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017378783A1 true AU2017378783A1 (en) | 2019-07-04 |
Family
ID=62627882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017378783A Abandoned AU2017378783A1 (en) | 2016-12-20 | 2017-12-15 | Cyclic dinucleotide sting agonists for cancer treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200113924A1 (https=) |
| EP (1) | EP3558324A4 (https=) |
| JP (1) | JP2020503303A (https=) |
| AU (1) | AU2017378783A1 (https=) |
| CA (1) | CA3047113A1 (https=) |
| RU (1) | RU2019122598A (https=) |
| WO (1) | WO2018118665A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912074PA (en) | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| US11033569B2 (en) | 2016-07-06 | 2021-06-15 | Sperovie Biosciences, Inc. | Compounds,Compositions, and methods for the treatment of disease |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| US11021511B2 (en) * | 2017-01-27 | 2021-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| CA3053568A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| WO2019043634A2 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ－スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| US11667663B2 (en) | 2017-08-31 | 2023-06-06 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| US11427610B2 (en) * | 2017-10-16 | 2022-08-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| JP7195317B2 (ja) | 2017-11-10 | 2022-12-23 | 武田薬品工業株式会社 | Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3820477A4 (en) | 2018-07-10 | 2022-07-13 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES |
| WO2020023361A1 (en) * | 2018-07-23 | 2020-01-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Enhancing anti-tumor response in melanoma cells with defective sting signaling |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| KR102567590B1 (ko) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트 |
| AU2019344398B2 (en) * | 2018-09-21 | 2022-09-22 | Shanghai De Novo Pharmatech Co., Ltd. | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application |
| AU2019371206A1 (en) | 2018-10-29 | 2021-05-27 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| WO2020092617A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| JP7621974B2 (ja) * | 2019-05-09 | 2025-01-27 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| AU2020310853A1 (en) | 2019-07-05 | 2022-01-27 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| US11033635B2 (en) | 2019-07-19 | 2021-06-15 | Immunesensor Therapeutics, Inc. | Antibody-STING agonist conjugates and their use in immunotherapy |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US20220395465A1 (en) * | 2019-09-25 | 2022-12-15 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| WO2021076666A1 (en) * | 2019-10-14 | 2021-04-22 | Immunesensor Therapeutics, Inc. | Methods of treating cancer with a sting agonist |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| JP2023533111A (ja) | 2020-05-15 | 2023-08-02 | イミューンセンサー セラピューティクス、インコーポレイテッド | 免疫チェックポイント阻害剤とのｓｔｉｎｇアゴニスト併用治療 |
| US12559514B2 (en) | 2020-05-22 | 2026-02-24 | Merck Sharp & Dohme Llc | Synthesis of fluorinated nucleotides |
| PE20230779A1 (es) | 2020-08-07 | 2023-05-09 | Gilead Sciences Inc | Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico |
| EP4295917A3 (en) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| US20240199680A1 (en) * | 2021-04-02 | 2024-06-20 | Merck Sharp & Dohme Llc | Synthesis of fluorinated cyclic dinucleotides |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022315305A1 (en) | 2021-07-23 | 2024-02-01 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
| EP4422686A1 (en) | 2021-10-26 | 2024-09-04 | Grant Demartino Industries LLC | Magnetostrictive piezoelectric nanoassembly as cancer chemotherapeutic |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2996472B1 (en) * | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| RS59500B1 (sr) * | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| EP3546473B1 (en) * | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CR20180101A (es) * | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
| CA3002236A1 (en) * | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| TWI704154B (zh) * | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| SG10201912074PA (en) * | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| WO2018100558A2 (en) * | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
-
2017
- 2017-12-15 WO PCT/US2017/066557 patent/WO2018118665A1/en not_active Ceased
- 2017-12-15 RU RU2019122598A patent/RU2019122598A/ru not_active Application Discontinuation
- 2017-12-15 CA CA3047113A patent/CA3047113A1/en not_active Abandoned
- 2017-12-15 AU AU2017378783A patent/AU2017378783A1/en not_active Abandoned
- 2017-12-15 US US16/472,043 patent/US20200113924A1/en not_active Abandoned
- 2017-12-15 JP JP2019533055A patent/JP2020503303A/ja not_active Withdrawn
- 2017-12-15 EP EP17884984.0A patent/EP3558324A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3047113A1 (en) | 2018-06-28 |
| JP2020503303A (ja) | 2020-01-30 |
| EP3558324A1 (en) | 2019-10-30 |
| RU2019122598A3 (https=) | 2021-04-06 |
| WO2018118665A1 (en) | 2018-06-28 |
| RU2019122598A (ru) | 2021-01-22 |
| EP3558324A4 (en) | 2020-08-05 |
| US20200113924A1 (en) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11285131B2 (en) | Benzo[b]thiophene STING agonists for cancer treatment | |
| AU2017378783A1 (en) | Cyclic dinucleotide sting agonists for cancer treatment | |
| US11312772B2 (en) | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment | |
| US20190328762A1 (en) | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment | |
| WO2025002280A1 (en) | Combination therapies for the treatment of cancer | |
| US11052065B2 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | |
| TW202502813A (zh) | 包含偶聯物的藥物組合的治療方法和用途 | |
| RU2771811C2 (ru) | БЕНЗО[b]ТИОФЕНОВЫЕ АГОНИСТЫ STING ДЛЯ ЛЕЧЕНИЯ РАКА | |
| US20230235077A1 (en) | Materials and methods of treating cancer | |
| WO2020033283A1 (en) | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc | |
| TW202502382A (zh) | 治療組合及其用途和治療方法 | |
| JP2025016420A (ja) | 非小細胞肺癌を治療するための併用療法 | |
| WO2025072041A1 (en) | Use of an immunoconjugate for the treatment of non-small cell lung cancer | |
| KR20240099363A (ko) | 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |